Effectiveness of rosiglitazone in reducing flexion contracture in a rabbit model of arthrofibrosis with surgical capsular release: A biomechanical, histological, and genetic analysis

J. D. Barlow, M. E. Morrey, R. U. Hartzler, D. Arsoy, S. Riester, Andre J van Wijnen, B. F. Morrey, J. Sanchez-Sotelo, Matthew Abdel

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Aims: Animal models have been developed that allow simulation of post-traumatic joint contracture. One such model involves contracture-forming surgery followed by surgical capsular release. This model allows testing of antifibrotic agents, such as rosiglitazone. Methods: A total of 20 rabbits underwent contracture-forming surgery. Eight weeks later, the animals underwent a surgical capsular release. Ten animals received rosiglitazone (intramuscular initially, then orally). The animals were sacrificed following 16 weeks of free cage mobilisation. The joints were tested biomechanically, and the posterior capsule was assessed histologically and via genetic microarray analysis. Results: There was no significant difference in post-traumatic contracture between the rosiglitazone and control groups (33° (standard deviation (SD) 11) vs 37° (sd14), respectively; p = 0.4). There was no difference in number or percentage of myofibroblasts. Importantly, there were ten genes and 17 pathways that were significantly modulated by rosiglitazone in the posterior capsule. Discussion: Rosiglitazone significantly altered the genetic expression of the posterior capsular tissue in a rabbit model, with ten genes and 17 pathways demonstrating significant modulation. However, there was no significant effect on biomechanical or histological properties.

Original languageEnglish (US)
Pages (from-to)11-17
Number of pages7
JournalBone and Joint Research
Volume5
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

rosiglitazone
Joint Capsule Release
Contracture
Rabbits
Capsules
Joints
Myofibroblasts
Microarray Analysis
Genes
Animal Models
Control Groups

Keywords

  • Arthrofibrosis
  • Joint contractures
  • Knee
  • Rosiglitazone
  • Surgical release

ASJC Scopus subject areas

  • Surgery
  • Orthopedics and Sports Medicine

Cite this

Effectiveness of rosiglitazone in reducing flexion contracture in a rabbit model of arthrofibrosis with surgical capsular release : A biomechanical, histological, and genetic analysis. / Barlow, J. D.; Morrey, M. E.; Hartzler, R. U.; Arsoy, D.; Riester, S.; van Wijnen, Andre J; Morrey, B. F.; Sanchez-Sotelo, J.; Abdel, Matthew.

In: Bone and Joint Research, Vol. 5, No. 1, 01.01.2016, p. 11-17.

Research output: Contribution to journalArticle

Barlow, J. D. ; Morrey, M. E. ; Hartzler, R. U. ; Arsoy, D. ; Riester, S. ; van Wijnen, Andre J ; Morrey, B. F. ; Sanchez-Sotelo, J. ; Abdel, Matthew. / Effectiveness of rosiglitazone in reducing flexion contracture in a rabbit model of arthrofibrosis with surgical capsular release : A biomechanical, histological, and genetic analysis. In: Bone and Joint Research. 2016 ; Vol. 5, No. 1. pp. 11-17.
@article{18882f58860f44edb403e1a4e914b788,
title = "Effectiveness of rosiglitazone in reducing flexion contracture in a rabbit model of arthrofibrosis with surgical capsular release: A biomechanical, histological, and genetic analysis",
abstract = "Aims: Animal models have been developed that allow simulation of post-traumatic joint contracture. One such model involves contracture-forming surgery followed by surgical capsular release. This model allows testing of antifibrotic agents, such as rosiglitazone. Methods: A total of 20 rabbits underwent contracture-forming surgery. Eight weeks later, the animals underwent a surgical capsular release. Ten animals received rosiglitazone (intramuscular initially, then orally). The animals were sacrificed following 16 weeks of free cage mobilisation. The joints were tested biomechanically, and the posterior capsule was assessed histologically and via genetic microarray analysis. Results: There was no significant difference in post-traumatic contracture between the rosiglitazone and control groups (33° (standard deviation (SD) 11) vs 37° (sd14), respectively; p = 0.4). There was no difference in number or percentage of myofibroblasts. Importantly, there were ten genes and 17 pathways that were significantly modulated by rosiglitazone in the posterior capsule. Discussion: Rosiglitazone significantly altered the genetic expression of the posterior capsular tissue in a rabbit model, with ten genes and 17 pathways demonstrating significant modulation. However, there was no significant effect on biomechanical or histological properties.",
keywords = "Arthrofibrosis, Joint contractures, Knee, Rosiglitazone, Surgical release",
author = "Barlow, {J. D.} and Morrey, {M. E.} and Hartzler, {R. U.} and D. Arsoy and S. Riester and {van Wijnen}, {Andre J} and Morrey, {B. F.} and J. Sanchez-Sotelo and Matthew Abdel",
year = "2016",
month = "1",
day = "1",
doi = "10.1302/2046-3758.51.2000593",
language = "English (US)",
volume = "5",
pages = "11--17",
journal = "Bone and Joint Research",
issn = "2046-3758",
publisher = "British Editorial Society of Bone and Joint Surgery",
number = "1",

}

TY - JOUR

T1 - Effectiveness of rosiglitazone in reducing flexion contracture in a rabbit model of arthrofibrosis with surgical capsular release

T2 - A biomechanical, histological, and genetic analysis

AU - Barlow, J. D.

AU - Morrey, M. E.

AU - Hartzler, R. U.

AU - Arsoy, D.

AU - Riester, S.

AU - van Wijnen, Andre J

AU - Morrey, B. F.

AU - Sanchez-Sotelo, J.

AU - Abdel, Matthew

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Aims: Animal models have been developed that allow simulation of post-traumatic joint contracture. One such model involves contracture-forming surgery followed by surgical capsular release. This model allows testing of antifibrotic agents, such as rosiglitazone. Methods: A total of 20 rabbits underwent contracture-forming surgery. Eight weeks later, the animals underwent a surgical capsular release. Ten animals received rosiglitazone (intramuscular initially, then orally). The animals were sacrificed following 16 weeks of free cage mobilisation. The joints were tested biomechanically, and the posterior capsule was assessed histologically and via genetic microarray analysis. Results: There was no significant difference in post-traumatic contracture between the rosiglitazone and control groups (33° (standard deviation (SD) 11) vs 37° (sd14), respectively; p = 0.4). There was no difference in number or percentage of myofibroblasts. Importantly, there were ten genes and 17 pathways that were significantly modulated by rosiglitazone in the posterior capsule. Discussion: Rosiglitazone significantly altered the genetic expression of the posterior capsular tissue in a rabbit model, with ten genes and 17 pathways demonstrating significant modulation. However, there was no significant effect on biomechanical or histological properties.

AB - Aims: Animal models have been developed that allow simulation of post-traumatic joint contracture. One such model involves contracture-forming surgery followed by surgical capsular release. This model allows testing of antifibrotic agents, such as rosiglitazone. Methods: A total of 20 rabbits underwent contracture-forming surgery. Eight weeks later, the animals underwent a surgical capsular release. Ten animals received rosiglitazone (intramuscular initially, then orally). The animals were sacrificed following 16 weeks of free cage mobilisation. The joints were tested biomechanically, and the posterior capsule was assessed histologically and via genetic microarray analysis. Results: There was no significant difference in post-traumatic contracture between the rosiglitazone and control groups (33° (standard deviation (SD) 11) vs 37° (sd14), respectively; p = 0.4). There was no difference in number or percentage of myofibroblasts. Importantly, there were ten genes and 17 pathways that were significantly modulated by rosiglitazone in the posterior capsule. Discussion: Rosiglitazone significantly altered the genetic expression of the posterior capsular tissue in a rabbit model, with ten genes and 17 pathways demonstrating significant modulation. However, there was no significant effect on biomechanical or histological properties.

KW - Arthrofibrosis

KW - Joint contractures

KW - Knee

KW - Rosiglitazone

KW - Surgical release

UR - http://www.scopus.com/inward/record.url?scp=84985893640&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84985893640&partnerID=8YFLogxK

U2 - 10.1302/2046-3758.51.2000593

DO - 10.1302/2046-3758.51.2000593

M3 - Article

AN - SCOPUS:84985893640

VL - 5

SP - 11

EP - 17

JO - Bone and Joint Research

JF - Bone and Joint Research

SN - 2046-3758

IS - 1

ER -